Radient Pharmaceuticals Expands Onko-Sure Commercialization to Include CLIA Lab-Based Testing Services

TUSTIN, CA, Apr 22 (MARKET WIRE) --
Through its US-based subsidiary AMDL Diagnostics Inc., Radient
Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today that
it plans to expand its worldwide commercialization strategy for its
Onko-Sure(TM) in vitro diagnostic (IVD) cancer test to include Clinical
Laboratory Improvement Amendments (CLIA) laboratory testing services in
the US and Canada through corporate partnerships beginning in the second
quarter FY2010.

RPC intends to supply Onko-Sure test kits; along with scientific proof
tools, marketing support and healthcare advocacy programs to select
partners in the US and Canada. RPC's partners are anticipated to commit
marketing resources to drive awareness and sales outreach to healthcare
professionals and the general public in the US and Canada for the CLIA
laboratory testing services. RPC expects that through this new service
its partner(s) will perform as many as 200,000 Onko-Sure cancer tests
through one or more CLIA laboratories in FY2010 and this additional sales
channel is anticipated to contribute to RPC reaching cash flow positive
operations by the end of the 3rd quarter of 2010.

According to Douglas MacLellan, Chairman and CEO of Radient
Pharmaceuticals, "RPC continues to make substantive progress in its 2010
Onko-Sure commercialization and outreach plan. This CLIA lab cancer
testing service can provide another comprehensive and potentially
life-saving cancer screening option that meets the growing cancer
challenges faced in the US and Canada."

Onko-Sure is a simple, non-invasive, patent-pending and
regulatory-approved in vitro diagnostic test for use as an aid in early
detection of cancer. Onko-Sure enables physicians and their patients to
effectively monitor and/or detect certain types of cancers by measuring
the accumulation of specific breakdown products in the blood called
Fibrin and Fibrinogen Degradation Products (FDP). FDP levels rise
dramatically with the progression of cancer. Onko-Sure is approved by the
US FDA for the monitoring of colorectal cancer and by Health Canada as a
lung cancer screen and cancer monitoring tool.

For additional information on Radient Pharmaceuticals, ADI and its
portfolio of products visit the Company's corporate website at
www.Radient-Pharma.com. For Investor Relations information contact
Kristine Szarkowitz at IR@Radient-Pharma.com or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California,
Radient Pharmaceuticals Corporation is an integrated pharmaceutical
company devoted to the research, development, manufacturing, and
marketing of diagnostic and therapeutic products.

Forward Looking Statements:
Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995: The statements contained in
this document include certain predictions and projections that may be
considered forward-looking statements under securities law. These
statements involve a number of important risks and uncertainties that
could cause actual results to differ materially including, but not
limited to, the performance of joint venture partners, as well as other
economic, competitive and technological factors involving the Company's
operations, markets, services, products, and prices. With respect to
Radient Pharmaceuticals Corporation, except for the historical
information contained herein, the matters discussed in this document are
forward-looking statements involving risks and uncertainties that could
cause actual results to differ materially from those in such
forward-looking statements.

Radient Pharma Contact:
Kristine Szarkowitz
Director-Investor Relations
kszarkowitz@radient-pharma.com
(Tel: ) 206.310.5323

Copyright 2010, Market Wire, All rights reserved.

-0-